Remuun receives CHF 150,000 from Venture Kick to promote targeted antibody therapies

The global market for monoclonal antibodies is expected to grow to over USD 300 billion by 2025. However, current antibody development processes are often slow, costly and limited in their therapeutic range, making it difficult to develop new therapies, particularly for cancer and diseases of the immune system.

Remuun has developed a patented MEGA platform that mimics the natural process of antibody diversification in the laboratory. Its modular design enables the rapid and precise production of customized monoclonal antibodies. Based on its expertise in the interactions between the immune system and tumors, Remuun aims to deepen scientific understanding and develop more effective immunotherapies.

The biotech startup plans to use the CHF 150,000 provided by Venture Kick to accelerate its growth. The funds will be used to build strategic partnerships with pharmaceutical companies, drive the development of a new generation of antibody-based therapies and expand the intellectual property portfolio.

The REMUUN team, co-founded by Prof. Dr. Richard Chahwan, consists of the scientists Paulina Wyrzykowska and Romina Fetti as well as other advisors. They bring diverse and complementary expertise to the development of innovative antibody therapies

"Venture Kick has provided Remuun with crucial support: The funding, mentoring and access to a broad network of experts have not only accelerated our research, but also sharpened our business strategy," says Richard Chahwan, founder and CEO of Remuun. "The process has challenged us to think bigger, evolve our vision and position Remuun as an innovator in antibody development. We greatly appreciate this support and look forward to the next steps."

More information